GALNT14 Involves the Regulation of Multidrug Resistance in Breast Cancer Cells.

GALNT14 is a member of N-acetylgalactosaminyltransferase enzyme family and mediates breast cancer cell development. Here, we find that GALNT14 regulates multidrug resistance (MDR) in breast cancer. The expression of GALNT14 is associated with MDR in breast cancer. Higher level of GALNT14 facilitates MCF-7 cells to resist Adriamycin, whereas knockdown of GALNT14 sensitizes cells to Adriamycin. Moreover, the expression of GALNT14 associates with the expression of P-gp, the efflux pump localized on the cell membrane, which could be the underlying mechanism of how GALNT14 induces MDR. In-depth analysis shows that GALNT14 regulates the stability of P-gp. Finally, GALNT14 associates with higher level of P-gp in chemotherapy-resistant human breast cancer tissues. Taken together, our studies reveal a molecular mechanism in breast cancer MDR.

GALNT14是N -乙酰半乳糖胺基转移酶家族的成员，介导乳腺癌细胞的发展。在此，我们发现GALNT14调节乳腺癌的多药耐药性（MDR）。GALNT14的表达与乳腺癌的多药耐药性相关。较高水平的GALNT14促进MCF - 7细胞对阿霉素产生耐药，而敲低GALNT14使细胞对阿霉素敏感。此外，GALNT14的表达与P - gp的表达相关，P - gp是位于细胞膜上的外排泵，这可能是GALNT14诱导多药耐药性的潜在机制。深入分析表明GALNT14调节P - gp的稳定性。最后，在化疗耐药的人类乳腺癌组织中GALNT14与较高水平的P - gp相关。综上所述，我们的研究揭示了乳腺癌多药耐药性的一种分子机制。